- Home
- IMRN vs ICU Comparison
IMRN vs ICU Comparison
Compare IMRN & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- ICU
- Stock Information
- Founded
- IMRN 1994
- ICU 2018
- Country
- IMRN Australia
- ICU United States
- Employees
- IMRN N/A
- ICU N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- ICU Health Care
- Exchange
- IMRN Nasdaq
- ICU Nasdaq
- Market Cap
- IMRN 9.2M
- ICU 9.5M
- IPO Year
- IMRN N/A
- ICU N/A
- Fundamental
- Price
- IMRN $1.72
- ICU $0.77
- Analyst Decision
- IMRN Strong Buy
- ICU
- Analyst Count
- IMRN 1
- ICU 0
- Target Price
- IMRN $5.00
- ICU N/A
- AVG Volume (30 Days)
- IMRN 656.2K
- ICU 6.3M
- Earning Date
- IMRN 09-08-2025
- ICU 08-12-2025
- Dividend Yield
- IMRN N/A
- ICU N/A
- EPS Growth
- IMRN N/A
- ICU N/A
- EPS
- IMRN N/A
- ICU N/A
- Revenue
- IMRN $4,048,286.00
- ICU $428,000.00
- Revenue This Year
- IMRN N/A
- ICU $754.07
- Revenue Next Year
- IMRN N/A
- ICU $100.09
- P/E Ratio
- IMRN N/A
- ICU N/A
- Revenue Growth
- IMRN 82.90
- ICU N/A
- 52 Week Low
- IMRN $1.50
- ICU $0.31
- 52 Week High
- IMRN $2.87
- ICU $9.56
- Technical
- Relative Strength Index (RSI)
- IMRN 45.31
- ICU 53.19
- Support Level
- IMRN $1.60
- ICU $0.51
- Resistance Level
- IMRN $1.80
- ICU $0.82
- Average True Range (ATR)
- IMRN 0.10
- ICU 0.12
- MACD
- IMRN -0.01
- ICU 0.04
- Stochastic Oscillator
- IMRN 34.09
- ICU 65.75
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.